Open an account

Attovia Therapeutics

ATTO · NASDAQ

$13.83−$0.67 (−4.62%)TodayMarket closed ·
Prev close $14.50

About ATTO

Attovia Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Carlos, California. The company went IPO on 2026-08-05. Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. The company is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Employees
0
Headquarters
San Carlos, California
Listed
Aug 5, 2026
Sector
N/A
Industry
N/A
Website
attovia.com

ATTO key statistics

Market cap
661.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
464.81K
Volume
330.64K
Open price
$14.36
High today
$14.75
Low today
$13.53
52 Week high
$28.00
52 Week low
$12.94

Attovia Therapeutics (ATTO) at a glance

As of Oct 23, 2026, Attovia Therapeutics (ATTO) shares are priced at $13.83, giving the company a market cap of 661.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.53 and $14.75. The current price is 2.2% above the day's low and 6.2% below its high.

Volume so far is 330.64K shares, below the average of 464.81K shares a day.

Over the past year Attovia Therapeutics has ranged from $12.94 to $28.00, and now sits 6% of the way up that range.

The average analyst price target is $43.04, 211.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $43.04
Low
$30.30
Now
$13.83
High
$54.60

ATTO news

  • Press releasePRNewswire

    Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.